The standard diagnostic tool deployed to fight Ebola outbreaks cannot detect Bundibugyo ebolavirus. It was designed for a different strain entirely.

That gap took weeks to close in the Democratic Republic of Congo. On July 2, the World Health Organization added the first Emergency Use Listing for a molecular diagnostic test targeting Bundibugyo virus — the strain driving one of the largest recorded outbreaks of this pathogen, with 1,406 laboratory-confirmed cases and 438 deaths as of the EUL announcement [1].

The GeneXpert assays that have become the default rapid-response tool in Ebola outbreaks were designed for Zaire ebolavirus. They do not reliably detect Bundibugyo [2]. Patients presenting with symptoms tested negative. They were not isolated. Transmission continued. The standard tool in the standard outbreak kit was the wrong tool for this outbreak, and the institutional apparatus did not catch it fast enough.

"During a fast-moving outbreak, timely access to quality-assured diagnostic tests can make a critical difference in containing transmission," said Dr. Yukiko Nakatani, WHO Assistant Director-General for Health Systems [1]. The statement is accurate. Its corollary is equally accurate: when the correct test does not exist, uncontained transmission fills the space.

Testing capacity in the affected provinces expanded from approximately 200 to 400 tests per day at two primary sites to more than 2,000 daily tests across ten laboratories following the EUL [1]. The laboratory infrastructure was present. The validated assay was not.

Researchers working on the outbreak have argued the problem is structural: outbreak response relies on pathogen-specific diagnostics rather than pathogen-agnostic systems capable of detecting any known hemorrhagic fever virus or flagging entirely novel pathogens [2]. When a strain falls outside the diagnostic's target, it escapes the net. The EUL for Bundibugyo is evidence that the lesson from previous outbreaks — build tools that do not require knowing the pathogen in advance — has not yet produced a systemic change.

The EUL does not retroactively close the gap the missing test opened. It makes the gap visible.

-- KENJI NAKAMURA, Tokyo